PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma

Wu,Huasheng; Ding,Fadian; Chen,Xijun; Chen,Shaoqin; Shi,Zhen; Liu,Qicai; Zheng,Zhenhua; Chen,Youting

doi:10.3892/ol.2019.11097

PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma

Authors:
- Huasheng Wu
- Fadian Ding
- Xijun Chen
- Shaoqin Chen
- Zhen Shi
- Qicai Liu
- Zhenhua Zheng
- Youting Chen
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, San Ming First Hospital, Sanming, Fujian 365000, P.R. China, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Critical Care Medicine, Xiamen Cardiovascular Hospital Xiamen University, Xiamen, Fujian 361000, P.R. China, Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China
Published online on: November 14, 2019 https://doi.org/10.3892/ol.2019.11097
Pages: 121-126
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognostic value of the genotype of the PRSS1 gene in patients with pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. The aim of the present study was to evaluate the association between the PRSS1 genotype and clinicopathological characteristics of patients with PDAC, as well as to explore the prognostic significance of the PRSS1 genotype in patients with PDAC. A total of 124 patients with PDAC patients were included in the current study and the PRSS1 genotype of the enrolled patients was determined by the polymerase chain reaction. Associations between the PRSS1 genotype and clinicopathological characteristics were subsequently analyzed using the Chi‑square test. The impact of the PRSS1 genotype on patient prognosis was assessed using the Kaplan‑Meier method, and predictive factors of overall survival (OS) time were analyzed by Cox regression. A total of 56 patients with PDAC (45.16%) had the T/C PRSS1 genotype, which was associated with large tumor sizes (P=0.027) and higher tumor node metastasis (TNM) stages (P=0.041). Following a median follow‑up of 19 months, the T/C genotype of PRSS1 genotype was associated with a shorter OS time (P=0.037) compared with the C/C or T/T PRSS1 genotypes. Univariate and multivariate analyses revealed that PRSS1 genotype was identified to be an independent prognostic factor for the OS time of patients with PDAC. The results obtained in the current study suggested that the PRSS1 genotype, as well as factors such as the serum level of carbohydrate antigen 19‑9 and the TNM stage, may act as independent prognostic factors for the OS time of patients with PDAC.

View Figures

View References

1	Ryan D, Hong T and Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014. View Article : Google Scholar : PubMed/NCBI
2	Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016. View Article : Google Scholar : PubMed/NCBI
3	Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS, et al: Five-year actual overall survival in resected pancreatic cancer: A contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol. 24:1722–1730. 2017. View Article : Google Scholar : PubMed/NCBI
4	Rulyak S, Lowenfels A, Maisonneuve P and Brentnall T: Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 124:1292–1299. 2003. View Article : Google Scholar : PubMed/NCBI
5	Huxley R, Ansary-Moghaddam A, Berrington De González A, Barzi F and Woodward M: Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer. 92:2076–2083. 2005. View Article : Google Scholar : PubMed/NCBI
6	Liu QC, Zhuang ZH, Zeng K, Cheng ZJ, Gao F and Wang ZQ: Prevalence of pancreatic diabetes in patients carrying mutations or polymorphisms of the PRSS1 gene in the Han population. Diabetes Technol Ther. 11:799–804. 2009. View Article : Google Scholar : PubMed/NCBI
7	Winter JM, Yeo CJ and Brody JR: Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 107:15–22. 2013. View Article : Google Scholar : PubMed/NCBI
8	Hausmann S, Kong B, Michalski C, Erkan M and Friess H: The role of inflammation in pancreatic cancer. Adv Exp Med Biol. 816:129–151. 2014. View Article : Google Scholar : PubMed/NCBI
9	Pinho A, Chantrill L and Rooman I: Chronic pancreatitis: A path to pancreatic cancer. Cancer Lett. 345:203–209. 2014. View Article : Google Scholar : PubMed/NCBI
10	Weiss F: Pancreatic cancer risk in hereditary pancreatitis. Front Physiol. 5:702014. View Article : Google Scholar : PubMed/NCBI
11	Whitcomb DC: Genetic risk factors for pancreatic disorders. Gastroenterology. 144:1292–1302. 2013. View Article : Google Scholar : PubMed/NCBI
12	Gao F, Li YM, Hong GL, Xu ZF, Liu QC, He QL, Lin LQ and Weng SH: PRSS1_p.Leu81Met mutation results in autoimmune pancreatitis. World J Gastroenterol. 19:3332–3338. 2013. View Article : Google Scholar : PubMed/NCBI
13	Gao F, Liu QC, Zhang S, Zhuang ZH, Lin CZ and Lin XH: PRSS1 intron mutations in patients with pancreatic cancer and chronic pancreatitis. Mol Med Rep. 5:449–451. 2012.PubMed/NCBI
14	Hengstler JG, Bauer A, Wolf HK, Bulitta CJ, Tanner B, Oesch F, Gebhard S and Boettger T: Mutation analysis of the cationic trypsinogen gene in patients with pancreatic cancer. Anticancer Res. 20:2967–2974. 2000.PubMed/NCBI
15	Rebours V, Boutron-Ruault M, Schnee M, Férec C, Maire F, Hammel P, Ruszniewski P and Lévy P: Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: A national exhaustive series. Am J Gastroenterol. 103:111–119. 2008. View Article : Google Scholar : PubMed/NCBI
16	Chen J and Férec C: Chronic pancreatitis: Genetics and pathogenesis. Annu Rev Genomics Hum Genet. 10:63–87. 2009. View Article : Google Scholar : PubMed/NCBI
17	Liu Q, Lin X, Liu J, Liu A and Gao F: The −409 C/T genotype of PRSS1 protects against pancreatic cancer in the Han Chinese population. Dig Dis Sci. 57:573–579. 2012. View Article : Google Scholar : PubMed/NCBI
18	Zeng K, Liu QC, Lin JH, Lin XH, Zhuang ZH, Gao F and Ou QS: Novel mutations of PRSS1 gene in patients with pancreatic cancer among Han population. Chin Med J (Engl). 124:2065–2067. 2011.PubMed/NCBI
19	Yi Q, Dong F, Lin L, Liu Q, Chen S, Gao F and He Q: PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer. Tumour Biol. 37:5805–5810. 2016. View Article : Google Scholar : PubMed/NCBI
20	Campa D, Pastore M, Capurso G, Hackert T, Di Leo M, Izbicki JR, Khaw KT, Gioffreda D, Kupcinskas J, Pasquali C, et al: Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Int J Cancer. 142:290–296. 2018. View Article : Google Scholar : PubMed/NCBI
21	Gargiulo S, Torrini M, Ollila S, Nasti S, Pastorino L, Cusano R, Bonelli L, Battistuzzi L, Mastracci L, Bruno W, et al: Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer. 8:547–553. 2009. View Article : Google Scholar : PubMed/NCBI
22	Fogelman D, Wolff R, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F and Abbruzzese J: Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 31:1417–1420. 2011.PubMed/NCBI
23	Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB III, MacDonald J and Willett CG: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol. 26:5918–5922. 2008. View Article : Google Scholar : PubMed/NCBI